-
公开(公告)号:US20210363231A1
公开(公告)日:2021-11-25
申请号:US17392943
申请日:2021-08-03
Applicant: Genentech, Inc.
Inventor: Amin FAMILI , Germaine FUH , Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL
Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
-
公开(公告)号:US20210115124A1
公开(公告)日:2021-04-22
申请号:US17129251
申请日:2020-12-21
Applicant: Genentech, Inc.
Inventor: Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL , Amin FAMILI , Germaine FUH
IPC: C07K16/22 , A61K47/60 , A61K47/61 , A61K39/395 , A61K47/34 , C07K14/475 , C07K16/44 , C07K16/46 , C12N15/10 , C12N15/115
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号:US20170096479A1
公开(公告)日:2017-04-06
申请号:US15274612
申请日:2016-09-23
Applicant: Genentech, Inc.
Inventor: Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL , Amin FAMILI , Germaine FUH
IPC: C07K16/22 , C07K16/46 , C12N15/10 , C12N15/115 , A61K47/34 , C07K16/44 , A61K39/395 , C07K14/475
CPC classification number: C07K16/22 , A61K39/3955 , A61K47/34 , A61K47/60 , A61K47/61 , A61K2039/505 , A61K2039/54 , C07K14/475 , C07K16/44 , C07K16/468 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C12N15/1037 , C12N15/115 , C12N2310/16
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号:US20160257744A1
公开(公告)日:2016-09-08
申请号:US15167030
申请日:2016-05-27
Applicant: Genentech, Inc.
Inventor: Germaine FUH , Chingwei V. LEE , Patrick KOENIG
IPC: C07K16/24 , A61K39/395 , A61K45/06
Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
Abstract translation: 本发明提供了双重特异性抗体及其制备和使用方法。 通常,双特异性抗体通过鉴定具有静电或疏水性的轻链可变区VL残基的单特异性抗体并且改变编码抗体VH中一个或多个溶剂可及残基的核酸序列, 与编码抗体VL的核酸序列的改变的组合。 表达改变的VH和VL,并选择双特异性抗体或其抗原结合片段。 还提供了示例性的双特异性抗体以及使用抗体的方法。
-
公开(公告)号:US20250109195A1
公开(公告)日:2025-04-03
申请号:US18980433
申请日:2024-12-13
Applicant: Genentech, Inc.
Inventor: Germaine FUH , Chingwei V. LEE , Patrick KOENIG
IPC: C07K16/24 , A61K39/00 , A61K39/395 , A61K45/06 , C07K16/46
Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
-
公开(公告)号:US20240279327A1
公开(公告)日:2024-08-22
申请号:US18648653
申请日:2024-04-29
Applicant: Genentech, Inc.
Inventor: Germaine FUH , Chingwei V. LEE , Patrick KOENIG
IPC: C07K16/24 , A61K39/00 , A61K39/395 , A61K45/06 , C07K16/46
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , C07K16/247 , C07K16/468 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92
Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
-
公开(公告)号:US20200255512A1
公开(公告)日:2020-08-13
申请号:US16860891
申请日:2020-04-28
Applicant: Genentech, Inc.
Inventor: Germaine FUH , Chingwei V. LEE , Patrick KOENIG
IPC: C07K16/24 , C07K16/46 , A61K45/06 , A61K39/395
Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
-
公开(公告)号:US20200002411A1
公开(公告)日:2020-01-02
申请号:US16572822
申请日:2019-09-17
Applicant: Genentech, Inc.
Inventor: Amin FAMILI , Germaine FUH , Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL
Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
-
公开(公告)号:US20200222547A1
公开(公告)日:2020-07-16
申请号:US16575749
申请日:2019-09-19
Applicant: Genentech, Inc. , Ascendis Pharma A/S
Inventor: Sebastian STARK , Thomas KNAPPE , Harald RAU , Nicola BISEK , Burkhardt LAUFER , Samuel WEISBROD , Tobias VOIGT , Germaine FUH , Patrick KOENIG , Chingwei Vivian LEE , Daniela BUMBACA YADAV
IPC: A61K47/61 , A61K47/69 , A61K39/395 , A61K9/00
Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.
-
公开(公告)号:US20190100581A1
公开(公告)日:2019-04-04
申请号:US16033499
申请日:2018-07-12
Applicant: Genentech, Inc.
Inventor: Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL , Amin FAMILI , Germaine FUH
IPC: C07K16/22 , C07K16/46 , A61K47/61 , C12N15/10 , C12N15/115 , C07K16/44 , A61K47/34 , A61K47/60 , C07K14/475 , A61K39/395 , A61K39/00
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
-
-
-
-
-
-
-
-